Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

References

• Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6
   PubMed Web of Science ®Google Scholar
• Markman M, Bookman MA. Second-line treatment of ovarian cancer. The Oncologist 2000; 5: 26–35
   PubMedGoogle Scholar
• Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′×2′ difluoredeoxycytidine 5′ triphosphate: A mechanism of self-potentiation. Cancer Res 1992; 52: 533–9
   PubMed Web of Science ®Google Scholar
• Carmichael J. The role of gemcitabine in the treatment of other tumors. Br J Cancer 1998; 78(Supp 3)7821–5
   Google Scholar
• Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530–3
   PubMed Web of Science ®Google Scholar
• Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89–93
   PubMed Web of Science ®Google Scholar
• Friedlander M, Milward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998; 9: 1343–5
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999; 10: 853–5
   PubMed Web of Science ®Google Scholar
• Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 1999; 22: 450–2
   PubMedGoogle Scholar
• D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 2003; 88: 266–9
   PubMed Web of Science ®Google Scholar
• Fowler WC, Jr, Van Le L. Gemcitabine as a single-agent treatment for ovarian cancer. Gynecol Oncol 2003; 90: S21–3
   Google Scholar
• Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 2003; 90: 593–6
   PubMed Web of Science ®Google Scholar
• Rustin G, Nelstrop A, McLean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545–51
   PubMed Web of Science ®Google Scholar
• Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21(Supp 10)187s–193
   Google Scholar
• Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, Hoskins WJ. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999; 17: 501–8
   PubMedGoogle Scholar
• Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Gwyther S, Bolis G, Gore M, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 1997; 8: 463–8
   PubMed Web of Science ®Google Scholar
• Thiesse P, Ollivier L, di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: Reasons for interobserver variability. J Clin Oncol 1997; 15: 3507–14
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312–22
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Vergote I, Du Bois A, et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian. Int J Gynecol Cancer 2005; 15(Suppl 1)36–41
   PubMedGoogle Scholar
• Sehouli J. Review of gemcitabine-based combinations for platinum resistant ovarian cancer. Int J Gynecol Cancer 2005; 15(Suppl 1)23–30
   PubMedGoogle Scholar
• Rose PG, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003; 88: 17–21
   PubMed Web of Science ®Google Scholar
• Garcia AA, O'Meara A, Bahador A, et al. Phase II of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2004; 93: 493–8
   PubMed Web of Science ®Google Scholar